Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238855 | 1.00 | NISCH (0.44) | NISCHLTA4HADRA2AADRA1AHTT | |
| SCHEMBL2323249 | 0.80 | NISCH (0.44) | NISCHADRA2AADRA1AHTTHTR1A | |
| SCHEMBL447010 | 0.80 | NISCH (0.44) | NISCHADRA2AADRA1AHTTHTR1A | |
| SCHEMBL76419 | 0.78 | CD274 (0.34) | LTA4H | |
| SCHEMBL76420 | 0.78 | CD274 (0.32) | LTA4H | |
| SCHEMBL25368890 | 0.77 | CA2 (0.45) | ADRA2AHTTDRD3MEN1LMNA | |
| SCHEMBL31238883 | 0.77 | CA2 (0.45) | ADRA2AHTTDRD3MEN1LMNA | |
| SCHEMBL22636270 | 0.77 | LMNA (0.43) | ADRA2AHTTDRD3MEN1LMNA | |
| SCHEMBL31238922 | 0.77 | LMNA (0.43) | ADRA2AHTTDRD3MEN1LMNA | |
| SCHEMBL7218131 | 0.75 | CA2 (0.47) | ADRA1AADRA1DADRA1BMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682124-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON IDAZOXAN SALT OR ONE OF ITS POLYMORPHS | PF MEDICAMENT (FR) | 2007-12-19 | — | — | EP | claimed |
| JP-2007509911-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682124-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON IDAZOXAN SALT OR ONE OF THE POLYMORPHS THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2006-07-26 | — | — | EP | claimed |
| US-20050176798-A1 | Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-08-11 | — | — | US | claimed |
| WO-2005041956-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON IDAZOXAN SALT OR ONE OF THE POLYMORPHS THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2005-05-12 | — | — | WO | claimed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4479365-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159145-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159145-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-8476307-B2 | pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs. | PIERRE FABRE MEDICAMENT (FR) | 2013-07-02 | — | — | US | disclosed |
| US-8124640-B2 | non-film-coated tablets comprising a mixture of 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride, microcrystalline cellulose, lubricants, colloidal silica and lactose, having stability | PIERRE FABRE MEDICAMENT (FR) | 2012-02-28 | — | — | US | disclosed |
| US-7595335-B2 | Containing microcrystalline cellulose, lubricant, colloidal silica and lactose; use in treating depression, Parkinson's disease and severe psychotic disorders, such as schizophrenia and schizoaffective disorders. | PIERRE FABRE MEDICAMENT (FR) | 2009-09-29 | — | — | US | disclosed |
| EP-0074711-A2 | Benzodioxane-imidazoline compounds, their preparation and use | SYNTEX (U.S.A.) INC. (US) | 1983-03-23 | — | — | EP | disclosed |
| EP-0058006-A1 | Imidazoline derivatives, process for the preparation thereof, pharmaceutical compositions containing them and their use | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1982-08-18 | — | — | EP | disclosed |
| WO-1982001874-A1 | 2-(1,4-BENZODOIOXAN-2-YLALKYL)IMIDAZOLES USEFUL AS ANTIDEPRESSANTS | SYNTEX INC (US) | 1982-06-10 | — | — | WO | disclosed |
| EP-0047531-A1 | 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-03-17 | — | — | EP | disclosed |
| US-4315021-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-02-09 | — | — | US | disclosed |
| US-4302469-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-24 | — | — | US | disclosed |
| US-4301171-A | 2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-17 | — | — | US | disclosed |
| EP-0033655-A2 | Imidazoline derivative, its salts, process for preparation and pharmaceutical compositions thereof | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1981-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176798-A1 | Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof | CYP3A43, ABCG2, CYP2C9 | NISCH 1222/4885LTA4H 3186/4885ADRA2A 64/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | NISCH 925/4885LTA4H 4254/4885ADRA2A 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.